10-K/A: Organon Amends 10-K, Reveals Sales Misconduct & Control Flaws

Organon & Co. filed an amended annual report disclosing an internal investigation into improper Nexplanon sales practices and material weaknesses in internal controls, leading to executive changes.

Summary

• Organon & Co. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, to reflect findings from an internal investigation.
• The investigation by the Audit Committee found that the company asked two U.S. wholesalers to purchase greater quantities of Nexplanon than demand in Q4 2022, Q3 & Q4 2024, and Q1, Q2, Q3 2025.
• The company waived inventory management fee performance metrics for these wholesalers, allowing them to receive fees despite exceeding inventory caps.
• Without these improper sales practices, consolidated revenue for fiscal year 2024 (and certain other relevant periods) would have fallen short of company guidance and/or external expectations.
• The incremental Nexplanon sales from these practices represented less than 1% of consolidated revenue for 2022 or 2024, and less than 2% for relevant quarterly periods.
• The investigation concluded that the former Chief Executive Officer and leader of the U.S. commercial organization applied inappropriate pressure, withheld information from the Board and auditors, and violated the company's Code of Conduct.
• No other executive leadership, including the CFO or financial reporting group, were found to be aware of the excess inventory purchases or waivers.
• The company identified material weaknesses in its internal control over financial reporting as of December 31, 2024, specifically related to 'tone at the top' and 'information and communication' components.
• Despite the material weaknesses, the company determined there will be no restatement or revision to its previously issued financial statements.
• Worldwide sales for the year ended December 31, 2024, increased by 2% to $6.403 billion, or 3% excluding unfavorable foreign exchange impacts of $77 million.
• Net income decreased to $864 million in 2024 from $1,023 million in 2023.
• Basic Earnings Per Share (EPS) was $3.36 in 2024, down from $4.01 in 2023.
• Nexplanon sales increased 16% to $963 million in 2024, including an estimated $15 million from the identified sales practices.
• The company acquired Dermavant Sciences Ltd. on October 28, 2024, for an upfront payment of $175 million, a $75 million milestone payment, and up to $950 million in commercial milestones.
• Organon expanded its agreement with Eli Lilly in 2024 to distribute Emgality and Rayvow in Europe and additional markets, involving upfront payments of $73 million and probable sales-based milestones of $260 million.
• Restructuring initiatives in 2024 and Q1 2025 are expected to result in an approximate 5% headcount reduction.
• Total potential payments for contractual milestones are $3.4 billion, with $218 million due within the next twelve months.
• The company declared a quarterly dividend of $0.28 per share payable on March 13, 2025.

Sentiment

Score: 3

Explanation: The filing reveals significant corporate governance failures and material weaknesses in internal controls, stemming from improper sales practices by former senior management. While the financial impact of the sales practices was small, the underlying control deficiencies and ethical breaches are serious. Although the company is taking remediation steps and has some positive product developments and acquisitions, the overall sentiment is negative due to the severity of the internal control issues and management misconduct, which overshadows modest revenue growth and strategic initiatives.

Positives

• Worldwide sales increased by 2% to $6.403 billion in 2024, or 3% excluding foreign exchange impacts.
• Nexplanon sales grew by 16% to $963 million in 2024, driven by increased demand and favorable pricing, despite the impact of improper sales practices.
• The acquisition of Dermavant Sciences Ltd. expands the dermatology portfolio with Vtama, which received FDA approval for atopic dermatitis in December 2024.
• Sales of Jada, a device for postpartum uterine bleeding, increased by 40% to $61 million due to continued uptake in the United States.
• Hadlima, a biosimilar, saw sales increase by 224% to $142 million, primarily due to its U.S. launch in July 2023.
• Diprospan sales increased by 52% to $139 million, recovering from prior manufacturing issues.
• The company expanded its distribution rights for migraine medicines Emgality and Rayvow with Eli Lilly, generating $107 million in sales in 2024.
• Net cash provided by operating activities increased to $939 million in 2024 from $799 million in 2023, reflecting favorable operating performance.
• The effective income tax rate was favorable at (7.1)% in 2024, partly due to the favorable closure of two non-U.S. tax audits and a $210 million valuation allowance release related to a Swiss tax asset.

Negatives

• Net income decreased by 15.5% to $864 million in 2024 from $1,023 million in 2023.
• Gross profit decreased by 1% to $3.715 billion in 2024 due to unfavorable price, foreign exchange, and higher inflation impacts.
• NuvaRing sales declined by 35% to $115 million due to ongoing generic competition and increased government discount rates in the U.S.
• Atozet sales declined by 9% to $473 million, primarily due to loss of exclusivity (LOE) in France, Spain, and Japan.
• Cozaar/Hyzaar sales declined by 14% to $243 million, impacted by volume-based procurement (VBP) in China and price reductions in Japan.
• Singulair sales decreased by 11% to $359 million due to decreased demand in China and Japan and price reductions in Japan.
• The company incurred $31 million in restructuring costs in 2024, with additional initiatives in Q1 2025 expected to result in a 5% headcount reduction.
• Net cash used in investing activities increased significantly to $513 million in 2024 from $260 million in 2023, largely due to acquisitions and milestone payments.
• The company's internal control over financial reporting was deemed ineffective as of December 31, 2024, due to material weaknesses related to 'tone at the top' and 'information and communication'.

Risks

• Expanded brand and class competition in operating markets.
• Difficulties with performance of third parties relied upon for business growth.
• Failure of any supplier to provide substances, materials, or services as agreed.
• Increased cost of supply, manufacturing, packaging, and operations.
• Difficulties developing and sustaining relationships with commercial counterparties.
• Competition from generic products as products lose patent protection, including Nexplanon (rod patents expire 2027, applicator patents 2030, international patents 2025-2026).
• Continued impact of the September 2024 LOE for Atozet.
• Disruptions at regulatory agencies like the FDA and SEC.
• Difficulties and uncertainties in implementing acquisition strategy or failure to recognize acquisition benefits.
• Pricing pressures globally, including managed care rules, governmental regulations, and pharmaceutical reimbursement.
• Impact of higher selling and promotional costs.
• Changes in government laws and regulations affecting research, development, approval, manufacturing, supply, distribution, marketing, and intellectual property.
• Efficacy, safety, or other quality concerns with marketed products leading to recalls, withdrawals, or declining sales.
• Delays or failures in demonstrating adequate efficacy and safety of product candidates in trials.
• Future actions of third parties, including changes in customer relationships or spending patterns of healthcare purchasers.
• Legal factors, including product liability claims (e.g., Fosamax, Nexplanon/Implanon), antitrust litigation, governmental investigations, and patent disputes (e.g., Xiromed Pharma Espana's challenge to Nexplanon patents).
• Lost market opportunity from delays and uncertainties in clinical trials and regulatory approval processes.
• Failure by the company or third-party collaborators/suppliers to fulfill regulatory or quality obligations.
• Cyberattacks or other failures/security breaches of IT systems.
• Increased focus on privacy issues and evolving legislative/regulatory landscape for privacy and data protection.
• Changes in tax laws, including those related to foreign earnings.
• Impact of any future pandemic, epidemic, or similar public health threat.
• Loss of key employees or inability to recruit new employees.
• Changes in accounting pronouncements adverse to the company.
• Economic factors beyond control, including changes in inflation, interest rates, recessionary pressures, and foreign currency exchange rates.
• Potential costs associated with optimizing manufacturing and supply network, including separation from Merck supply agreements through 2031.

Future Outlook

The company expects continued significant decline in sales of Atozet in 2025 due to loss of exclusivity. Volume-based procurement (VBP) in China is anticipated to continue impacting the established brands product portfolio for the next several quarters. NuvaRing sales are also expected to continue declining due to generic competition. The company plans to implement additional restructuring initiatives in Q1 2025, leading to an approximate 5% headcount reduction, to drive operational efficiencies. Sales recovery for Diprospan is expected to continue over the next twelve months. The company believes its financing arrangements, future cash from operations, and access to capital markets will provide adequate resources to fund future cash flow needs. The company is also optimizing its manufacturing and supply network, including planned exits from Merck supply agreements through 2031, to redefine its sourcing strategy and focus on efficiencies.

Management Comments

• Management, in consultation with the Audit Committee, re-assessed the effectiveness of the company's disclosure controls and procedures and its internal control over financial reporting as of December 31, 2024.
• Management concluded that there were material weaknesses in the company's internal control over financial reporting as of December 31, 2024, and that previous assessments should no longer be relied upon.
• Management has concluded that its consolidated financial statements included in the Original Form 10-K, which are also included in their entirety in this Amendment, continue to fairly present, in all material respects, our financial position and results as of December 31, 2024 and 2023, and as of and for each of the years in the three-year period ended December 31, 2024, notwithstanding the material weaknesses.
• Management is responsible for establishing and maintaining adequate internal control over financial reporting.
• Management has developed a remediation plan to address the material weaknesses in internal control over financial reporting, with the oversight of its Audit Committee.

Industry Context

Organon operates in a highly competitive and regulated pharmaceutical industry, facing challenges from generic competition for its established brands, such as NuvaRing and Atozet, which are experiencing significant sales declines post-LOE. The company is strategically expanding its portfolio through acquisitions and licensing, particularly in immuno-dermatology (Dermavant's Vtama) and migraine treatments (Eli Lilly's Emgality and Rayvow), to diversify beyond its core women's health and established brands. The biosimilars market, where Organon has products like Hadlima, continues to grow as a more affordable alternative to high-cost biologics, presenting a significant opportunity. Global trends like declining birthrates are prompting favorable policies for fertility solutions, which Organon is addressing with products like SJ02. The company also navigates government pricing pressures, such as volume-based procurement (VBP) in China, which negatively impacts its established brands.

Comparison to Industry Standards

• The identified material weaknesses in internal control over financial reporting, particularly regarding 'tone at the top' and 'information and communication,' indicate a significant deviation from best practices in corporate governance and financial oversight within the pharmaceutical industry. Such weaknesses are typically viewed negatively by investors and regulators, as they can undermine the reliability of financial reporting.
• The improper sales practices for Nexplanon, while representing a small percentage of overall revenue (<1%), highlight a lapse in ethical sales conduct that is inconsistent with the high standards expected of publicly traded pharmaceutical companies. This could lead to reputational damage and potential regulatory scrutiny, similar to past cases involving other pharmaceutical companies facing sales practice investigations.
• Organon's strategy of acquiring and licensing new assets like Dermavant's Vtama and Eli Lilly's Emgality/Rayvow aligns with broader industry trends where pharmaceutical companies seek to bolster their pipelines and diversify revenue streams in the face of patent expirations and generic competition. This is a common approach to maintain growth in a mature market.
• The decline in sales for established brands like Atozet, NuvaRing, Cozaar/Hyzaar, and Singulair due to generic competition and pricing pressures (e.g., VBP in China) is a standard challenge across the pharmaceutical industry. Companies like Teva Pharmaceutical Industries Ltd. and Sandoz (Novartis's former generics unit) are examples of companies that thrive on generic competition, while innovators like Organon must continuously innovate or acquire to offset these losses.

Management Changes

Corporate Governance

Legal Proceedings

• Fosamax Litigation: Approximately 975 cases in Federal court, 1,740 in New Jersey state court, and 275 in California state court, alleging femur fractures and other bone injuries. The Third Circuit ruled in September 2024 that plaintiffs' failure-to-warn claims are not preempted by federal law, leading to further litigation in the Femur Fracture MDL.
• Nexplanon/Implanon Product Liability: Two filed product liability actions and 56 unfiled (tolled) cases in the U.S. involving Implanon, alleging similar injuries. 20 cases pending outside the U.S. (11 Implanon, 9 Nexplanon).
• Microspherix LLC Patent Litigation (Nexplanon): Settled in December 2023 for patent infringement claims related to Nexplanon manufacturing, use, sale, and importation. Payments of $35 million (Dec 2023), $25 million (Aug 2024), and $20 million (Jan 2025) were made.
• Xiromed Pharma Espana, S.L. (Nexplanon Generic Challenge): Received a Paragraph IV Certification Letter on February 24, 2025, notifying the company of an abbreviated new drug application seeking approval to market a generic version of Nexplanon prior to the expiration of U.S. Patent Nos. 8,722,037 and 9,757,552 (expiring 2027 and 2030, respectively). The company intends to defend its intellectual property rights.
• Governmental Proceedings: Subsidiaries may receive inquiries and be subject to preliminary investigation activities from competition and/or other governmental authorities, which could lead to formal proceedings and potential monetary fines or remedial undertakings. Organon assumed liability for matters related to products transferred from Merck.
• Environmental Matters: Accrued liabilities for environmental matters totaled $16 million at December 31, 2024, with estimated expenditures of $14 million for 2025-2029. No material adverse effect on financial condition, results of operations, or liquidity is expected.

Related Party Transactions

• Transition Services Agreements with Merck: Merck and its affiliates provided various interim, transitional services to Organon, and vice versa. The majority of Merck services terminated by July 2, 2023, with certain services extended. As of December 31, 2024, no material TSAs remain.
• Interim Operating Model (IOM) Agreements with Merck: Merck entities continued to market, import, and distribute Organon products in various jurisdictions until licenses transferred. Organon recognized economic benefits and burdens. As of December 31, 2024, only one jurisdiction remains under an IOM agreement.
• Manufacturing and Supply Agreements with Merck: Merck manufactures and supplies certain active pharmaceutical ingredients and formulated/packaged products for Organon, and Organon manufactures/supplies for Merck. Sales from these agreements were $108 million in 2024.
• Tax Matters Agreement with Merck: Allocates responsibility for U.S. federal, state, and foreign income/non-income taxes, and provides for cooperation on tax matters. Merck is generally responsible for taxes prior to the Separation and certain taxes resulting from the Separation. Organon is responsible for taxes exclusively related to its business and for breaches of representations/covenants.
• Employee Matters Agreement with Merck: Allocated assets, liabilities, and responsibilities related to employee compensation and benefit plans. Organon recorded a $50 million 'grow-in provision' for future service earned by transferred employees under Merck's pension and postretirement plans.
• Receivables from Merck: $148 million as of December 31, 2024 (down from $583 million in 2023).
• Payables to Merck: $362 million as of December 31, 2024 (down from $619 million in 2023).
• Agreement to acquire Oss Bio-Tech manufacturing facility from Merck for $25 million, with payments in Q3 2025 and H1 2026.

Stakeholder Impact

• Shareholders: Negative impact due to revelations of improper sales practices, material weaknesses in internal controls, and executive misconduct, which could erode investor confidence and potentially lead to share price volatility. The decrease in net income and EPS also directly impacts shareholder returns. However, the declared dividend provides some return.
• Employees: Restructuring initiatives in 2024 and Q1 2025 will result in an approximate 5% headcount reduction, leading to job losses. The misconduct of the former CEO and U.S. commercial leader could negatively affect employee morale and trust in leadership.
• Customers (Wholesalers): Directly impacted by the improper sales practices, being asked to purchase excess Nexplanon inventory and receiving waivers for inventory management fees. This could strain relationships and affect future purchasing patterns.
• Customers (Patients/Providers): Continued availability of key products like Nexplanon, Vtama, Emgality, and Rayvow. The focus on women's health and biosimilars aims to provide innovative and affordable solutions.
• Regulatory Authorities (SEC, FDA, etc.): The SEC filing itself is a response to regulatory requirements following an internal investigation. The identified material weaknesses and improper sales practices will likely lead to increased scrutiny from the SEC and potentially other regulatory bodies, requiring significant remediation efforts.
• Creditors: The company's long-term debt and contractual obligations remain substantial. While refinancing efforts have extended maturities and lowered some interest rates, the internal control issues could be a concern for lenders regarding financial reporting reliability.

Next Steps

• Implement enhanced Code of Conduct, compliance training, and Annual Ethics and Policy Certifications.
• Implement additional representations within the Quarterly Financial Certification Questionnaire.
• Enhance existing Disclosure Committee responsibilities and provide incremental training.
• Implement additional and enhance existing sub-certifications and internal management representation letters, including training.
• Enhance controls and implement written policies and procedures for timely communication of management fee arrangements with wholesalers.
• Evaluate and enhance internal controls related to sales monitoring.
• Continue to assess future impacts of the Inflation Reduction Act of 2022.
• Continue sales recovery for Diprospan over the next twelve months.
• Complete the acquisition of the Oss Bio-Tech manufacturing facility from Merck in Q3 2025, with a $15 million payment, and the remaining $10 million in H1 2026.
• Monitor the ongoing Fosamax and Nexplanon/Implanon product liability litigation.
• Defend and enforce intellectual property rights for Nexplanon against the Paragraph IV Certification from Xiromed Pharma Espana, S.L.
• Continue to optimize the manufacturing and supply network, including planned exits from Merck supply agreements through 2031.

Key Dates

Recommendation

The filing reveals significant corporate governance issues and material weaknesses in internal controls, stemming from improper sales practices by former senior management. This is a serious concern that could lead to reputational damage and potential regulatory penalties, despite the company stating no financial restatement is required. While Organon has taken decisive action by replacing the CEO and initiating a comprehensive remediation plan, the effectiveness and timeline of these changes are uncertain. The company's financial performance shows mixed results, with overall revenue growth but declining net income and EPS. Strategic acquisitions and growth in certain product lines (Nexplanon, Hadlima, Jada) are positive, but are offset by declines in other established brands due to generic competition. Given the ongoing internal control remediation, the potential for further legal or regulatory scrutiny, and the mixed financial performance, a 'hold' recommendation is appropriate. Investors should monitor the progress of the remediation efforts and the impact of new management before making further investment decisions. The stock carries elevated risk due to these internal issues, but the underlying business segments still hold value.

Keywords

Pharmaceuticals, Women's Health, Biosimilars, Established Brands, Nexplanon, Internal Controls, SEC Filing, 10-K/A, Sales Practices, Corporate Governance, Drug Development, Acquisitions, Dermavant, Vtama, Eli Lilly, Emgality, Rayvow, Generic Competition, Patent Litigation, Financial Reporting, Healthcare, Contraception, Fertility, Dermatology, Cardiovascular, Respiratory, Oncology, Immunology